Orion Portfolio Solutions LLC Sells 5,041 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Orion Portfolio Solutions LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,072 shares of the biopharmaceutical company’s stock after selling 5,041 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Halozyme Therapeutics were worth $1,247,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in HALO. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $29,000. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust increased its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $59.77 on Friday. The stock has a market capitalization of $7.38 billion, a PE ratio of 17.43, a PEG ratio of 0.42 and a beta of 1.32. The business’s 50 day simple moving average is $59.82 and its 200 day simple moving average is $54.93. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of research reports. Benchmark reaffirmed a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $62.78.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,200 shares of company stock worth $1,786,668. Company insiders own 2.90% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.